GEO series

Expression correlates of the full-length androgen receptor and its splicing variants

GSE36549 Homo sapiens (human) Expression microarray 14 samples Submitted 2012/03/17 Platform GPL4133

At a glance

Expression microarray · human · 14 samples

What it is: Expression microarrayGene activity read on a chip (the older technology that RNA-seq replaced).
Organism: Homo sapiens (human)
Topic: Prostate cancerThis series is part of our curated briefing on it.
Samples: 14 samples: 14 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed expression table (series matrix) and the array files, from NCBI.

Summary (written by the submitters)

Continued androgen receptor (AR) signaling is an established mechanism underlying castration-resistant prostate cancer (CRPC), and suppression of AR signaling remains a therapeutic goal of CRPC therapy. Constitutively active androgen receptor splicing variants (AR-Vs) lack the AR ligand-binding domain (AR-LBD), the intended target of androgen deprivation therapies (ADT) including new CRPC therapies such as abiraterone and MDV3100.

Read the full summary ↓

While the canonical full-length AR (AR-FL) and AR-Vs are both increased in CRPC, their expression regulation, associated transcriptional programs, functional relationships, and respective roles in mediating responses to endocrine therapies have not been dissected. In this study, we show that suppression of canonical AR-FL signaling by targeting AR-LBD leads to increased AR-V expression in two cell line models of CRPC. Importantly, treatment-induced AR-Vs activate a distinct expression signature enriched for cell cycle genes without requiring the presence of AR-FL. Conversely, activation of AR-FL signaling suppresses the AR-V signature but activates expression programs mainly associated with macromolecular synthesis, metabolism, and differentiation. In prostate cancer cells and CRPC xenografts treated with MDV3100 and abiraterone, increased expression of two constitutively active AR-Vs, AR-V7 and ARV567ES, but not AR-FL, parallels increased expression of the AR-driven cell cycle gene UBE2C. In addition, protein expression of AR-V7, but not AR-FL, is positively correlated with UBE2C in clinical CRPC specimens. The cumulative in vitro and in vivo evidence support an adaptive shift toward AR-V-mediated signaling in at least a subset of CRPC tumors as the AR-LBD is rendered inactive, suggesting an important mechanism contributing to drug resistance to CRPC therapies.

This dataset

Open GSE36549 in finder → Find more human microarray datasets → Prostate cancer landscape →

Download · which file do I need?

Direct links to NCBI, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need.

All supplementary files ↗

3 · The original raw files

Whole study · RAW.tar

Everything the authors deposited as one archive (GSE36549_RAW.tar), including the raw array or instrument files. Can be large; the picker in step 2 takes just the samples you need.

Whole study · RAW.tar ↓

What the files usually look like: For arrays the series matrix is normally the normalised expression table you want; the raw array files (CEL and similar) are in the RAW.tar.

Also filed as BioProject PRJNA153421. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 22710436) ↗

Study design

14 samples, each with a distinct title — no replicated groups

Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.

How we read this: Read from 14 sample titles: 14 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM896744 LNCaP_Vector_CSS
GSM896745 LNCaP_V7_CSS
GSM896746 LNCaP_Vector_R1881
GSM896747 LNCaP_V7_R1881
GSM896748 LNCaP95_ControlsiRNA_CSS
GSM896749 LNCaP95_LBDsiRNA_CSS
GSM896750 LNCaP95_DBDsiRNA_CSS
GSM896751 LNCaP95_ControlsiRNA_R1881
GSM896752 LNCaP95_LBDsiRNA_R1881
GSM896753 LNCaP95_DBDsiRNA_R1881
GSM896756 VCaP_DMSO_R1881
GSM896757 VCaP_MDV_R1881
GSM896990 VCaP_ControlsiRNA_R1881
GSM896991 VCaP_LBDsiRNA_R1881

More Prostate cancer datasets

GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing
GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing
GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing
GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing
GSE270928 Single-cell sequencing of full-length transcripts and T-cell receptors with automated high-throughput Smart-seq3 [HT SS3] 6415 samples shares full-length, receptor
GSE222196 Treatment of prostate cancer cell lines with Androgen Receptor and Receptor Tyrosine Kinase inhibitors 246 samples shares androgen, receptor

Search all human microarray datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.